18-Fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin's B-cell lymphoma

Show simple item record

dc.contributor.author Shelly, M. J.
dc.contributor.author McDermott, S.
dc.contributor.author O'Connor, Owen J.
dc.contributor.author Blake, M. A.
dc.date.accessioned 2016-07-13T13:29:51Z
dc.date.available 2016-07-13T13:29:51Z
dc.date.issued 2012
dc.identifier.citation Shelly, M. J., McDermott S., O'Connor O. J. and Blake M. A. (2012) '18-Fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin's B-cell lymphoma', ISRN Hematology, 456706. http://dx.doi.org/10.5402/2012/456706 en
dc.identifier.startpage 456706 (1) en
dc.identifier.endpage 456706 (9) en
dc.identifier.issn 2090-441X
dc.identifier.issn 2090-4428
dc.identifier.uri http://hdl.handle.net/10468/2869
dc.identifier.doi 10.5402/2012/456706
dc.description.abstract 18-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of benefit in the management of aggressive B-cell non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and advanced stage follicular lymphoma. The combination of anatomic and functional imaging afforded by FDG-PET/CT has led to superior sensitivity and specificity in the primary staging, restaging, and assessment of response to treatment of hematological malignancies when compared to FDG-PET and CT alone. The use of FDG-PET/CT for post treatment surveillance imaging remains controversial, and further study is needed to ascertain whether this modality is cost effective and appropriate for use in this setting. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Hindawi Publishing Corporation en
dc.rights © 2012 M. J. Shelly et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en
dc.rights.uri https://creativecommons.org/licenses/by/3.0/ en
dc.subject Lymphoma en
dc.subject FDG-PET/CT en
dc.subject Fluorodeoxyglucose en
dc.subject Non-Hodgkin's lymphoma en
dc.title 18-Fluorodeoxyglucose positron emission tomography/computed tomography in the management of aggressive non-Hodgkin's B-cell lymphoma en
dc.type Article (non peer-reviewed) en
dc.internal.authorcontactother Owen J. O'Connor, Medicine , University College Cork, Cork, Ireland. +353-21-490-3000 Email: oj.oconnor@ucc.ie en
dc.internal.availability Full text available en
dc.date.updated 2012-09-26T15:26:16Z
dc.description.version Published Version en
dc.internal.rssid 169067281
dc.description.status Not peer reviewed en
dc.identifier.journaltitle IRSN Hematology en
dc.internal.copyrightchecked No. !!CORA!! Yes en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress oj.oconnor@ucc.ie en
dc.identifier.articleid 456706
dc.identifier.articleid


Files in this item

Icon
Name: FDG_IN_AGGRESSIVE ...
Size: 1.124Mb
Format: PDF
Description: Published Version
View/Open

This item appears in the following Collection(s)

Show simple item record

© 2012 M. J. Shelly et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Except where otherwise noted, this item's license is described as © 2012 M. J. Shelly et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement